Brief Summary

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

Status
Available
EA Type
Individual Patients
Interventions

Biological: Nivolumab plus Relatlimab FDC

Countries
Australia
Israel
Italy
Switzerland
United States
Locations

Local Institution
San Francisco, California, 94143

Available

Investigator: Site 0029

University of Colorado Cancer Center, Anschutz Cancer Pavilion
Aurora, Colorado, 80045

Available

Investigator: Theresa Medina, Site 0017

Local Institution
Washington, District of Columbia, 20007

Available

Investigator: Site 0023

Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207

Available

Investigator: John Vu, Site 0021

Local Institution
Tampa, Florida, 33612

Available

Investigator: Site 0019

Dreiling Schmidt Cancer Institute
Hays, Kansas, 67601

Available

Investigator: Anthony Accurso, Site 0002

Local Institution
Boston, Massachusetts, 02114

Available

Investigator: Site 0013

Local Institution
Burlington, Massachusetts, 01805

Available

Investigator: Site 0037

Local Institution
New York, New York, 10022

Available

Investigator: Site 0010

Local Institution
New York, New York, 10022

Available

Investigator: Site 0025

Local Institution
Syracuse, New York, 13210

Available

Investigator: Site 0004

Novant Health
Winston-Salem, North Carolina, 27103

Available

Investigator: Heather Shearer, Site 0011

Inova Schar Cancer Institute
Fairfax, Virginia, 22031

Available

Investigator: Sekwon Jang, Site 0001

Contacts

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Investigators

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

Sponsors / Collaborators
Bristol-Myers Squibb
NCT Number
NCT05170685
MeSH Terms
Nivolumab